NYSE · Healthcare
Merck & Co., Inc. (MRK) stock research
Merck & Co., Inc. (MRK) is listed on NYSE. Merck & Co., Inc. reported revenue of $65.0B in the fiscal year that ended on 2025-12-31. Revenue rose 1.3% from the year before. Merck & Co., Inc.’s net income for that year was $18.3B. The SEC classifies it under Pharmaceutical Preparations. It is incorporated in New Jersey. Its most recent SEC filing is Form 8-K (current report), filed on 2026-10-13.
Open MRK in Willow. Filings, fundamentals, recent news — sourced stock research, no recommendation.
Annual financials
As tagged by Merck & Co., Inc. in its annual reports on SEC EDGAR. The latest year is from Form 10-K, filed on 2026-02-24.
| Fiscal year ended | Revenue | Net income | Diluted EPS | Cash and equivalents |
|---|---|---|---|---|
| 2025-12-31 | $65.0B | $18.3B | $7.28 | $14.6B |
| 2024-12-31 | $64.2B | $17.1B | $6.74 | $13.2B |
| 2023-12-31 | $60.1B | $365.0M | $0.14 | $6.8B |
Recent SEC filings
Filed with the SEC under CIK 0000310158. Every row is read from the filing itself on EDGAR, not from a summary of it.
- 8-K (current report) filed 2026-10-13 · period ending 2026-10-09
- 10-Q (quarterly report) filed 2026-08-07 · period ending 2026-06-30
- 8-K (current report) filed 2026-08-04 · period ending 2026-08-04
- 8-K (current report) filed 2026-05-28 · period ending 2026-05-26
- 8-K (current report) filed 2026-05-22 · period ending 2026-05-22
- 10-Q (quarterly report) filed 2026-05-04 · period ending 2026-03-31
Filing history read from SEC EDGAR on 2026-10-19.
What a Willow brief on MRK checks
- Recent filings and company disclosures.
- TTM fundamentals and valuation context.
- Recent news and market context separated from primary filings.
- Bull case, bear case, key risks, and watch-next items in a non-directional register.
Questions about MRK
- What was Merck & Co., Inc.’s revenue in the fiscal year ended 2025-12-31?
- $65.0B for the fiscal year that ended on 2025-12-31, as reported in Form 10-K filed on 2026-02-24.
- Was Merck & Co., Inc. profitable in the fiscal year ended 2025-12-31?
- Yes. It reported net income of $18.3B for the fiscal year that ended on 2025-12-31.
- What were Merck & Co., Inc.’s diluted earnings per share in the fiscal year ended 2025-12-31?
- $7.28 per diluted share for the fiscal year that ended on 2025-12-31.
- How much cash did Merck & Co., Inc. hold at the end of the fiscal year ended 2025-12-31?
- $14.6B in cash and cash equivalents on 2025-12-31.
- What is Merck & Co., Inc.’s most recent SEC filing?
- Form 8-K (current report), filed on 2026-10-13. brief.finance reads it directly from SEC EDGAR.
- When does Merck & Co., Inc.’s fiscal year end?
- Its SEC registration lists the year end as 31 December. The annual figures on this page cover the fiscal year that ended on 2025-12-31.
- What is Merck & Co., Inc.’s SEC CIK number?
- 0000310158. EDGAR uses this Central Index Key to identify every filing the company submits.
- What does a Willow brief on MRK include?
- Recent SEC filings, fundamentals and valuation context, price history, and both a bull case and a bear case. Every figure links to the source it came from.
- Does brief.finance say whether to buy or sell MRK?
- No. brief.finance publishes educational research and does not recommend buying, selling, or holding any security.
Primary source paths
- SEC EDGAR company filings search
- Nasdaq market activity page
- brief.finance methodology and source checks
More Healthcare research hubs
- ABBV — AbbVie Inc.
- ABT — Abbott Laboratories
- AMGN — Amgen Inc.
- BIIB — Biogen Inc.
- BMY — Bristol-Myers Squibb Company
- CI — The Cigna Group
- CVS — CVS Health Corporation
- DHR — Danaher Corporation
- Browse all Healthcare research hubs
Author and editorial responsibility
By Joseph, Founder and editor, brief.finance. Every brief is generated under a fixed editorial and compliance method operated by Reaktif LLC.
About the author · Disclosures · Stock Directory
Ticker catalog last updated 2026-10-19.